ICUI on Nasdaq

ICU Medical

Logo: icumed.com5

Medical technology company

ICU Medical, Inc. is a medical technology company based in San Clemente, California.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1984Founded1

Compare with Teleflex, Insulet (United States) or Globus Medical, or pick any stock.

  • TickerICUI on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersSan Clemente1
  • Websitewww.icumed.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address951 Calle Amanecer, San Clemente, Ca 92763-62126
  • Filer categoryLarge accelerated filer6
  • LEI5493003NRW7LS2QZRH604
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 22846464

See how the biggest companies compare on our leaderboards

ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, and hemodynamic monitoring systems.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

36.8%Gross margin8
1.9%Operating margin8
0.0%Net margin8
-6.3%Revenue growth, 20258
0.0%Return on equity8
0.60×Debt to equity8
$91.8MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Infusion Consumables brought in 50% of the revenue ICU Medical broke down this way in fiscal 2025.

  1. Infusion Consumables$1.1B850%up 7% from 2024
  2. Infusion Systems$684.2M831%up 5% from 2024
  3. Vital Care$437.9M820%down 37% from 2024
Products and services by year
Products and services202320242025
Infusion Consumables$969.1M$1.0B$1.1B
Infusion Systems$629.0M$652.4M$684.2M
Vital Care$661.0M$690.8M$437.9M

Regions

United States brought in 61% of the revenue ICU Medical broke down this way in fiscal 2025.

  1. United States$1.4B861%down 11% from 2024
  2. EMEA$411.7M818%up 5% from 2024
  3. APAC$232.9M810%up 0% from 2024
  4. Other foreign countries$230.6M810%up 3% from 2024
Regions by year
Regions202320242025
United States$1.4B$1.5B$1.4B
EMEA$373.6M$393.5M$411.7M
APAC$241.7M$232.8M$232.9M
Other foreign countries$203.8M$223.6M$230.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue63¢$1.4B
  • Research and development4¢$87.5M
  • Selling, general and admin28¢$625.2M
  • Other costs1¢$12.8M
  • Interest4¢$93.3M
  • Income tax0¢$2.4M
  • Profit0¢$732.0K

Out of $2.2B in revenue.8

Where each dollar of operating cash went, fiscal 2025

  • Capital spending49¢$88.0M
  • Share buybacks5¢$8.8M
  • Kept or used elsewhere46¢$83.0M

Out of $179.8M of cash from operations.8

Financial statements

Revenue91011128$2.2B in 2025+76% since 2019
0$1.0B$2.0B$3.0B2019: $1.3B$1.3B20192020: $1.3B$1.3B2020+0%2021: $1.3B$1.3B2021+4%2022: $2.3B$2.3B2022+73%2023: $2.3B$2.3B2023−1%2024: $2.4B$2.4B2024+5%2025: $2.2B$2.2B2025−6%
Gross profit91011128$822.0M in 2025+74% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $471.9M$471.9M20192020: $461.5M$461.5M2020−2%2021: $491.5M$491.5M2021+6%2022: $697.8M$697.8M2022+42%2023: $739.9M$739.9M2023+6%2024: $824.8M$824.8M2024+11%2025: $822.0M$822.0M2025−0%
Operating income91011128$42.8M in 2025−60% since 2019
-$50.0M0$50.0M$100.0M$150.0M2019: $107.4M$107.4M20192020: $98.2M$98.2M2020−9%2021: $123.2M$123.2M2021+26%2022: -$42.9M-$42.9M20222023: $22.8M$22.8M20232024: $43.0M$43.0M2024+88%2025: $42.8M$42.8M2025−0%
Net income91011128$732.0K in 2025−99% since 2019
-$200.0M-$100.0M0$100.0M$200.0M2019: $101.0M$101.0M20192020: $86.9M$86.9M2020−14%2021: $103.1M$103.1M2021+19%2022: -$74.3M-$74.3M20222023: -$29.7M-$29.7M2023−60%2024: -$117.7M-$117.7M2024+297%2025: $732.0K$732.0K2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Revenues$2.2B$2.4B$2.3B
Cost of Goods Sold$1.4B$1.6B$1.5B
Gross profit$822.0M$824.8M$739.9M
Selling, general and administrative$625.2M$638.8M$606.7M
Research and development$87.5M$88.6M$85.3M
Restructuring, strategic transaction and integration expenses$66.5M$59.8M$41.3M
Change in fair value of contingent earn-out$0-$5.4M-$16.2M
Total operating expenses$779.2M$781.8M$717.0M
Income from operations$42.8M$43.0M$22.8M
Interest Expense, Net-$83.0M-$95.8M-$95.2M
OTHER EXPENSE, NET-$232.0K-$13.2M-$5.9M
Gain (Loss) on Disposition of Business$44.8M$0$0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total$4.4M-$66.0M-$78.3M
(Provision) benefit for income taxes-$2.4M-$51.7M$48.6M
Income (Loss) from Continuing Operations before Equity Method Investments$1.9M-$117.7M-$29.7M
Income (Loss) from Equity Method Investments-$1.2M$0$0
Net Income (Loss)$732.0K-$117.7M-$29.7M
Basic$0.03-$4.83-$1.23
Diluted$0.03-$4.83-$1.23
Basic (in shares)24.6M shares24.4M shares24.1M shares
Diluted (in shares)24.9M shares24.4M shares24.1M shares

Compare ICU Medical with another company

The story

The company was founded in 1984 by George "Doc" Lopez, MD who developed a product known as the ClickLock to better secure IV lines.

In 2006, ICU Medical introduced its first products for oncology. The ChemoClave system from ICU Medical is a closed system transfer device (CSTD) that allows pharmacists and nurses to safely mix and administer hazardous drugs used to treat cancer patients without exposing themselves to these drugs.

ICU Medical acquired the former Abbott Laboratories Critical Care business from Hospira in 2009 following a four-year business arrangement in which ICU acted as the manufacturer of the Hospira critical care product line. In February 2017 ICU Medical also acquired the Hospira Infusion Systems business from Pfizer.

From Wikipedia’s article on ICU Medical, shared under CC BY-SA 4.0.7

Leadership

Who has led ICU Medical, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven Riggs2013–2014

Chair

  1. George A. Lopez2006–2013

President

  1. Daniel Woolson2026–now

Chief financial officer

  1. Francis J. Obrien2007–2008
  2. Scott E. Lamb2016–2020
  3. Brian Michael Bonnell2020–now

Chief operating officer

  1. Christian B. Voigtlander2018–now
1990200020102020
Board members and other officers (22)

Products and brands

ICU Medical's Neutron device aims to reduce catheter occlusion caused by external factors such as connecting and disconnecting a luer, or patient vascular pressure changes caused by coughing, sneezing, crying or vomiting.

In 2015, ICU Medical acquired Excelsior Medical Corporation, a manufacturer of healthcare devices used to disinfect and protect access into a patient's bloodstream. Acquired products included the SwabCap and SwabFlush, as well as pre-filled saline and heparin flush syringes. The total purchase price for Excelsior was $59.5 million, however ICU immediately sold the operating assets of SwabFlush and pre-filled syringe businesses to Medline Industries, Inc. for $27 million.

Oncology

ICU Medical's oncology product line is designed specifically to keep healthcare workers and patients safe from exposure to hazardous drugs. In 2012, the company introduced the Diana Hazardous drug compounding system, a user-controlled automated system that helps protect clinicians from exposure to hazardous drugs and accidental needlesticks while protecting the patient preparation from exposure to environmental contaminants.

Critical care

ICU Medical's line of critical care products provides real-time hemodynamic monitoring, blood conservation solutions, oximetry catheter technology that helps optimize oxygen supply and demand, critical care catheters with no natural rubber latex components, and hemodynamic transducer kits. In addition, ICU Medical's line of advanced sensor catheters, having no natural rubber latex components, helps keep patients safe from potentially lethal allergic reactions.

From Wikipedia’s article on ICU Medical, shared under CC BY-SA 4.0.7

Timeline

  1. Dec 23, 2013New chief executive Steven Riggs becomes CEO16
  2. 1984Founded Founded1

Filings

322 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 36 major events, 159 insider forms, 35 large holders, 72 other. The latest 20:

  1. Sep 3, 2026144 EDGAR
  2. Sep 3, 20264 PRIMARY DOCUMENT EDGAR
  3. Sep 1, 2026144 EDGAR
  4. Sep 1, 20264 PRIMARY DOCUMENT EDGAR
  5. Aug 31, 2026144 EDGAR
  6. Aug 31, 20264 PRIMARY DOCUMENT EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 13, 2026144 EDGAR
  9. Aug 13, 20264 PRIMARY DOCUMENT EDGAR
  10. Aug 13, 2026SCHEDULE 13G/A EDGAR
  11. Aug 12, 20264 PRIMARY DOCUMENT EDGAR
  12. Aug 12, 2026144 EDGAR
  13. Aug 11, 2026144 EDGAR
  14. Aug 11, 2026144 EDGAR
  15. Aug 11, 20264 PRIMARY DOCUMENT EDGAR
  16. Aug 11, 20264 PRIMARY DOCUMENT EDGAR
  17. Aug 6, 202610-Q EDGAR
  18. Aug 6, 20268-K EDGAR
  19. Jun 1, 2026SD EDGAR
  20. May 22, 2026144 EDGAR

The 322 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

74 open-market trades by officers, directors and large owners since October 2021: 3 buys and 71 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 3, 2026Sanzone Virginia RuthVP, General CounselSale4,856$168.69$819.2KForm 4
Sep 1, 2026Bonnell Brian MichaelChief Financial OfficerSale6,381$175.00$1.1MForm 4
Aug 31, 2026Bonnell Brian MichaelChief Financial OfficerSale9,307$172.79$1.6MForm 4
Aug 13, 2026Woolson DanielVP, GM-Infusion CapitalSale5,417$181.33$982.3KForm 4
Aug 12, 2026Sousa BenChief Information OfficerSale2,250$178.32$401.2KForm 4
Aug 11, 2026Voigtlander Christian B.Chief Operating OfficerSale8,929$182.93$1.6MForm 4
Aug 11, 2026FINNEY ELISHA WDirectorSale378$182.48$69.0KForm 4
May 22, 2026Woolson DanielVP, GM-Infusion CapitalSale2,123$132.21$280.7KForm 4
May 14, 2026Sanzone Virginia RuthVP, General CounselSale2,447$124.08$303.6KForm 4
May 12, 2026Greenberg David C.DirectorSale2,424$122.91$297.9KForm 4
Nov 25, 2025Woolson DanielVP, GM-Infusion CapitalSale2,897$152.35$441.4KForm 4
Nov 11, 2025Sanzone Virginia RuthVP, General CounselSale930$142.35$132.4KForm 4
Nov 11, 2025FINNEY ELISHA WDirectorSale1,285$140.42$180.4KForm 4
Aug 27, 2025Greenberg David C.DirectorBuy1,200$126.41$151.7KForm 4
Aug 14, 2025Jain VivekChairman and CEOBuy21,929$112.83$2.5MForm 4
May 30, 2025Sanzone Virginia RuthVP, General CounselSale700$133.62$93.5KForm 4
May 28, 2025Voigtlander Christian B.Chief Operating OfficerSale4,985$128.50$640.6KForm 4
May 27, 2025Voigtlander Christian B.Chief Operating OfficerSale4,945$131.00$647.8KForm 4
May 23, 2025Voigtlander Christian B.Chief Operating OfficerSale4,959$130.00$644.7KForm 4
May 22, 2025Voigtlander Christian B.Chief Operating OfficerSale4,959$130.03$644.8KForm 4

All 74 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.3,753,409$550.2M0.0%+145,087
Jupiter Topco LLC2,781,620$407.8M0.2%New
Vanguard Portfolio Management LLC1,470,583$215.6M0.0%+32,907
Fuller & Thaler Asset Management, Inc.1,298,127$190.3M0.5%+77,588
Vanguard Capital Management LLC1,123,237$164.7M0.0%+11,362
Dimensional Fund Advisors LP1,053,476$154.4M0.0%+69,674
State Street Corp1,024,369$150.2M0.0%+56,316
Schroder Investment Management Group739,138$109.3M0.1%+37,858
Ameriprise Financial Inc689,573$101.1M0.0%+83,845
Geode Capital Management, LLC660,423$96.8M0.0%+49,204
River Road Asset Management, LLC626,290$91.8M1.0%−20,140
Citadel Advisors LLC536,225$78.6M0.0%+202,889
Neuberger Berman Group LLC451,279$66.2M0.0%+4,860
Jpmorgan Chase & Co440,468$65.3M0.0%−27,349
Goldman Sachs Group Inc417,342$61.2M0.0%+94,651
Morgan Stanley372,583$54.6M0.0%−154,259
Bank Of America Corp /de/368,754$54.1M0.0%+37,015
Toronto Dominion Bank358,023$52.5M0.1%+149,091
Charles Schwab Investment Management Inc331,052$48.5M0.0%+8,573
Nomura Asset Management International Inc.328,969$48.2M0.1%+34,650
Reinhart Partners, Llc.314,768$46.1M1.1%New
Silvercrest Asset Management Group LLC297,505$43.6M0.3%−26,171
Northern Trust Corp295,779$43.4M0.0%+2,080
Fmr LLC283,195$41.5M0.0%−29,728
Federated Hermes, Inc.243,438$35.7M0.1%−14,060

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
May 6, 2025Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+13.6%Report
Oct 31, 2024Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+37.8%Report
Feb 14, 2022Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−99.8%Report
Dec 23, 2020Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+130.8%Report
Dec 21, 2020Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+129.1%Report
Sep 25, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−145.1%Report
Sep 24, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$15,001 - $50,000−147.4%Report
Sep 23, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−149.1%Report
Mar 31, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−216.6%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Company websiteICU Medical logo
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55